Lilly’s COVID treatment sparks little demand
For a highly touted drug meant to keep throngs of people out of hospitals during a pandemic, Eli Lilly and Co.’s wonder treatment bamlanivimab sure has been slow to catch on.
Eli Lilly and Co.
Articles
Demand surprisingly low for COVID-19 antibody drugs, but shortages still loom
Red tape, staff shortages, testing delays and strong skepticism are keeping many patients and doctors from the drugs made by Eli Lilly and Co. and Regeneron Pharmaceuticals.
Eli Lilly shares rise on Prevail acquisition, optimistic forecast
Lilly stock climbed Tuesday after the drugmaker laid out a better-than-expected revenue forecast and plans to buy a young company developing a potential Parkinson’s disease treatment.
Study: Drug combo with Lilly medication boosts COVID recovery time
Doctors are reporting that a two-drug treatment involving a medication from Indianapolis-based Eli Lilly and Co. is especially helpful for COVID-19 patients who need extra oxygen.
CVS to give Eli Lilly therapy to COVID-19 patients at home
The medication will be provided by the U.S. government, which paid Indianapolis-based Lilly $375 million for an initial two-month supply of 300,000 doses as part of the Operation Warp Speed program.
Lilly starting new trial for COVID-19 antibody, potentially widening already red-hot market
Lilly said it will enroll up to 500,000 people in its latest study, with at least 5,000 people expected to receive bamlanivimab therapy. The drugmaker is partnering with health insurer UnitedHealth Group to see if the drug will help high-risk people.
CVS prepares to administer Lilly antibody drug, as feds buy 650,000 more doses for $812.5M
CVS has developed a program to provide the treatments in their homes, but it won’t be available—at least initially—in Indianapolis.
Health experts clash over use of certain drugs for COVID-19
In a separate development, the FDA on Thursday gave emergency authorization to use of another anti-inflammatory drug sold by Eli Lilly, baricitinib, to be used with remdesivir.
Lilly arthritis drug gets FDA emergency use authorization for COVID-19 patients
The Indianapolis drugmaker said Thursday evening it was awarded an emergency use authorization for its drug baricitinib to be used in combination with Gilead Sciences’ antiviral drug remdesivir in severely ill, hospitalized patients with COVID-19.
Trump officials promise fair distribution of Lilly’s new COVID-19 antibody drug
Because of the initial limited supply, the number of doses each state receives will be determined by the number of confirmed cases and hospitalizations in a given week, federal officials said.
Lilly’s COVID-19 treatment expected to be in short supply initially
The initial scarcity of the drug and the logistical complexities of administering it could mute its immediate impact on the pandemic and raise questions about whether it is being distributed to people in the greatest need.
U.S. allows emergency use of Lilly’s COVID-19 antibody drug
The Food and Drug Administration on Monday cleared the experimental drug from Indianapolis-based Eli Lilly and Co. for people 12 and older with mild or moderate COVID-19 not requiring hospitalization. It’s a one-time treatment given through an IV.
Lilly signs $375M deal with government for experimental COVID-19 treatment
Eli Lilly and Co. said Wednesday that the U.S. government will accept 300,000 vials of the drug, called bamlanivimab, if the Food and Drug Administration grants emergency authorization for its use.
Lilly still bullish on COVID-19 therapy, despite end of trial
Although federal officials pulled the plug on a trial testing a Lilly antibody drug for people hospitalized with COVID-19, other studies for the therapy are continuing on populations that could become big markets.
Eli Lilly to acquire biotech firm in deal that could grow to more than $1.3B
Eli Lilly and Co. on Thursday announced that it has agreed to acquire Disarm Therapeutics, a private biotechnology company that is developing therapies that could be used to treat multiple sclerosis, glaucoma, Alzheimer’s disease and ALS.
Eli Lilly says other antibody trials ongoing after pause in one study
Lilly said it is reviewing safety data that caused federal researchers to pause a trial of the company’s COVID-19 antibody treatment in hospitalized patients. Other trials using lower doses of the drug outside the hospital will continue.
Eli Lilly pauses trial enrollment for COVID-19 antibody treatment over safety concern
Indianapolis-based Eli Lilly and Co. said it made the decision on recommendation of the Data and Safety Monitoring Board “out of an abundance of caution.”
Antibody drugs are no cure but seem promising for COVID-19
Experimental antibody drugs like the one President Trump was given and the one Eli Lilly is developing are among the most promising therapies being tested for treating and preventing coronavirus infections. Here’s how they work.
Lilly bracing for global demand for its experimental antibody for COVID-19
Shares of Lilly jumped 3.7%, or $5.41, to $149.54 in afternoon trading following the company’s morning announcement that it has asked the U.S. government to allow emergency use of the therapy to treat the disease.
Lilly seeks emergency use of its antibody drug for COVID-19
Eli Lilly and Co. says it has asked the U.S. government to allow emergency use of an experimental antibody therapy based on positive early results from a study.